Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study
| Autor: | Arslan Tekatas, Sema Inanir, Sebahattin Albayrak, Dürdane Aksoy, Yusuf Gençten, Fikret Erdemir, Volkan Solmaz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Urology Urinary Bladder Venlafaxine Logistic regression lcsh:RC870-923 urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Clinical Investigation Validation Studies Prospective cohort study Sertraline business.industry Urinary Bladder Overactive Incidence (epidemiology) Beck Depression Inventory medicine.disease lcsh:Diseases of the genitourinary system. Urology humanities female genital diseases and pregnancy complications Antidepressive Agents Neurology Overactive bladder Antidepressant Original Article Neurology (clinical) business 030217 neurology & neurosurgery Overactive medicine.drug |
| Zdroj: | International Neurourology Journal International Neurourology Journal, Vol 21, Iss 1, Pp 62-67 (2017) |
| Popis: | WOS:000397737200010 PubMed: 28361516 Purpose: In this study, we investigated overactive bladder (OAB) functions in male patients who used antidepressant drugs (ADs) that were previously examined in female patients, based on conflicting data in literature regarding the effects of AD on OAB and the differences between male and female urinary system physiologies (anatomical and hormonal). Methods: The study included 202 male patients (a control group of 90 healthy subjects, and an experimental group of 112 patients taking ADs for different disorders). All the patients completed the overactive bladder-validated 8 (OAB-V8) questionnaire, the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and the Beck Depression Inventory (BDS). Results: The OAB-V8, ICIQ-SF, and BDS scores for the antidepressant users were significantly higher than those of the control group. The highest prevalence of OAB symptoms was observed in patients taking venlafaxine (68.2%), and the lowest prevalence was in patients taking sertraline (28.0%). Moreover, the frequency of OAB between the antidepressant groups was statistically significant. The univariate logistic regression analyses showed a significant relationship between the presence of OAB, antidepressant usage, BDS score, and the age of a patient. In the multivariate logistic regression analyses, the association between the presence of OAB and antidepressant usage was statistically significant. Conclusions: The present study showed that the incidence of OAB and the severity of OAB symptoms increased in males using antidepressants for various disorders. This may have been due to unique pharmacological effects, on a molecular or individual level, of serotonin-norepinephrine reuptake inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|